Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF. | Open Forum Infect Dis;8(8): ofab403, 2021 Aug. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF.

Pohlman, F Will; McGee, Kara S; McKellar, Mehri S.

Affiliation

Pohlman FW; Duke University School of Medicine, Durham, North Carolina, USA.
McGee KS; Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA.
McKellar MS; Duke University School of Nursing, Durham, North Carolina, USA.

Open Forum Infect Dis ; 8(8): ofab403, 2021 Aug.

Article in En | MEDLINE | ID: mdl-34430674

Key words

HIV; integrase; tenofovir alafenamide; weight gain

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Open Forum Infect Dis Year: 2021 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Open Forum Infect Dis Year: 2021 Document type: Article Affiliation country: Country of publication: